دورية أكاديمية
أعرض في EDS

Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: A systematic review.

التفاصيل البيبلوغرافية
العنوان: Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: A systematic review.
المؤلفون: Mulder, Renée L., Kremer, Leontien C.M., Santen, Hanneke M. van, Ket, Jan Lucas, Trotsenburg, A.S. Paul van, Koning, Caro C.E., Meeteren, Antoinette Y.N. Schouten-van, Caron, Huib N., Neggers, Sebastian J.C.M.M., Dalen, Elvira C. van
المصدر: Cancer Treatment Reviews; Nov2009, Vol. 35 Issue 7, p616-632, 17p
مستخلص: Summary: Background: Growth hormone deficiency (GHD) is usually the first and most frequent endocrine problem occurring after cranial radiotherapy (CRT). The aim of this systematic review was to evaluate the existing evidence of the prevalence and risk factors of radiation-induced GHD in childhood cancer survivors. Methods: MEDLINE, EMBASE and CENTRAL were searched for studies reporting on radiation-induced GHD in childhood cancer survivors. Information about study characteristics, prevalence and risk factors was abstracted and the quality of each study was assessed. A meta-regression analysis was performed. Results: The prevalence of radiation-induced GHD was estimated in 33 studies. Most studies had methodological limitations. The prevalence varied considerably between 0% and 90.9%. Selecting only the studies with adequate peak GH cut-off limits (<5μg/L) resulted in 3 studies. In these studies the prevalence ranged from 29.0% to 39.1%, with a pooled prevalence of 35.6%. Higher CRT dose and longer follow-up time have been suggested to be the main risk factors of GHD by studies included in this review. The meta-regression analysis showed that the wide variation in the prevalence of GHD could be explained by differences in maximal CRT dose. Conclusions: GHD is a frequent consequence after CRT in childhood cancer survivors. The prevalence of radiation-induced GHD ranged from 29.0% to 39.1% when selecting only studies with adequate peak GH cut-off limits. Higher CRT dose and longer follow-up time are the main risk factors. More well-designed studies are needed to accurately estimate the prevalence of GHD and to define the exact CRT threshold dose. [Copyright &y& Elsevier]
Copyright of Cancer Treatment Reviews is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Supplemental Index
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا